Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)

Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN): a Retrospective Study of Patients Diagnosed in France From 2000 to 2013

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02859623

Acronym

LpDC

Enrollment

Registered

2016-08-09

Start date

2014-01-31

Completion date

Unknown

Last updated

2016-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematological Malignancies

Brief summary

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected organs are usually the skin, bone marrow, lymph nodes and the central nervous system. Patients with BPDCN have poor outcomes with median overall survival (OS) ranging in the largest series of patients from 8 to 12 months. Patient care must be defined in this pathology. Despite 40%-90% complete remission (CR) rates after initial chemotherapy, relapses are almost inevitable. The investigators have developed a national network to collect clinical and biological data of French patients diagnosed with BPDCN.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) from January 2000 to June 2013 in France. * Diagnosis should be established by hematology laboratory of French blood Agency of Bourgogne Franche-Comté and/or by anatomopathological analysis (realized in local centres or by Tony Petrella at Dijon University Hospital) according to phenotypic and anatomopathological criteria published in the literature.

Exclusion criteria

* No

Design outcomes

Primary

Measure	Time frame	Description
description of the efficacy of treatments for BPDCN	from the diagnosis to death or until June 2013, date of end of data collection	Measurement of the overall survival for all patients from the date of diagnostic until death or end of data collection

Secondary

Measure	Time frame	Description
description of biological profiles of patients	from the diagnosis to death or until June 2013, end of data collection	immunophenotyping profile
complete remission rate	from the diagnosis to death or until June 2013, end of data collection	—
mean duration of the first remission	from the diagnosis to death or until June 2013, end of data collection	—
description of clinical profiles of patients	from the diagnosis to death or until June 2013, end of data collection	presence of cutaneous lesions
non-responders rate	from the diagnosis to death or until June 2013, end of data collection	—
time interval between two treatments	from the diagnosis to death or until June 2013, end of data collection	—
mortality without relapse	from the diagnosis to death or until June 2013, end of data collection	—
survival without events	from the diagnosis to death or until June 2013, end of data collection	—

Outcome results